Save up -80% on Levocetirizine
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Xyzal
|$11.04||30 tablets/5 mg|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Xyzal coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Levocetirizine every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Levocetirizine volume of distribution
The terminal elimination half-life was 5.7 +/- 0.2 hours, the oral clearance was 0.82 +/- 0.05 mL/min/kg, and the volume of distribution was 0.4 +/- 0.02 L/kg. Compared with predose areas, the wheals and flares produced by histamine phosphate were significantly decreased from 1 to 28 hours, inclusive (P < .05).
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Levocetirizine
Levocetirizine is a third-generation non-sedative antihistamine indicated for the relief of symptoms associated with seasonal and perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria. It was developed from the second-generation antihistamine cetirizine. Levocetirizine is the R-enantiomer of the cetirizine racemate. Levocetirizine is an inverse agonist that decreases activity at histamine H1 receptors. This in turn prevents the release of other allergy chemicals and increased blood supply to the area, and provides relief from the typical symptoms of hay fever. It does not prevent the actual release of histamine from mast cells. Levocetirizine was approved by the United States Food and Drug Administration on May 25, 2007 and is marketed under the brand XYZAL by sanofi-aventis U.S. LLC.
Levocetirizine mechanism of action
Levocetirizine, the active enantiomer of cetirizine, is an anti-histamine; its principal effects are mediated via selective inhibition of H1 receptors. The antihistaminic activity of levocetirizine has been documented in a variety of animal and human models. In vitro binding studies revealed that levocetirizine has an affinity for the human H1-receptor 2-fold higher than that of cetirizine (Ki = 3 nmol/L vs. 6 nmol/L, respectively). This increased affinity has unknown clinical relevance.
Dosage forms of Levocetirizine
|Xyzal Oral Solution||0.5mg/mL||200mL Solution||$75.00|
Camber Pharmaceuticals, Inc.
Humans and other mammals
Indication of Levocetirizine
Levocetirizine is indicated for the relief of symptoms associated with allergic rhinitis (seasonal and perennial) in adults and children 6 years of age and older.
Toxicity of Levocetirizine
Uncertainty factor (UF) regarding the uncertainty associated with the toxicity of the surrogate compound.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Levocetirizine on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.
Get lower price on Levocetirizine now!
What is a Xyzal?
Xyzal is a drug with a pronounced antihistamine and antiallergic effect. The active component of the drug Xyzal – levocetirizine is the R-enantiomer of cetirizine. Levocetirizine competitively blocks the H1-histamine receptors, and the pharmacological activity of levocetirizine is almost 2 times higher than that of cetirizine.
Xyzal affects the histamine-dependent phase of the allergic reaction. In addition, levocetirizine reduces eosinophil migration and decreases vascular permeability. Xyzal also slightly slows down the release of cytokines and inflammatory mediators.
The drug has antipruritic and antiexudative action, facilitates the course and prevents the development of allergic reactions. Levocetirizine has almost no effect on cholinergic and serotonin receptors, and does not have a significant sedative effect.
After oral administration, levocetirizine is well absorbed in the intestinal tract. Taking the drug at the same time as eating does not change the bioavailability and rate of absorption of levocetirizine. The peak plasma concentration of the active substance is reached within 1 hour after ingestion. Equilibrium plasma concentrations are achieved on the second day of therapy with levocetirizine.
The degree of connection of levocetirizine with plasma proteins reaches 90%, oral bioavailability is 100%. Slightly metabolized in the body. Excreted mainly by the kidneys by tubular secretion and glomerular filtration. About 13% of levocetirizine is excreted by the intestines. The half-life varies from 6 to 10 hours depending on the individual characteristics of the patient. In children, the half-life of levocetirizine is shortened.
In patients with impaired renal function, an increased half-life is observed. During hemodialysis, levocetirizine is practically not excreted (during the 4-hour hemodialysis, no more than 10% of levocetirizine is excreted).